he establishment of the method for prediction of therapeutic antibody and the search of the prognostic factors

• Project/Area Number: 19590170
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Japanese Foundation For Cancer Research
• Principal Investigator: MISHIMA Yuji Japanese Foundation For Cancer Research, 癌化学療法センター・臨床部, 研究員 (10442550)
• Project Period (FY): 2007 – 2008
• Project Status: Completed (Fiscal Year 2008)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2007: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
• Keywords: 抗体医薬 / 感受性予測 / 生細胞イメージング / 共焦点顕微鏡 / 癌 / 薬剤反応性 / イメージング

Research Abstract

抗体医薬は、副作用が少なくがんの治療効果を高める反面、治療費が高額になる傾向があり、医療経済学の観点から、効果の期待のできない患者に対する投与は避けることが重要である。そのためには治療効果を正確に予測する技術が必要とされている。本課題では、各種抗体医薬の効果予測技術を確立することを目的とし、顕微鏡下で生きたがん細胞の抗体医薬に対する感受性を評価する方法を確立することで、迅速かつ被験者への負担の少ない診断法を開発した。

Research Products

• [Journal Article] An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy (2009)
  • Author(s): Mishima Y, Sugimura N, et al
  • Journal Title: Clinical Cancer Research 15(10) Pages: 3624-3624
  • Peer Reviewed
• [Journal Article] Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma (2009)
  • Author(s): Terui Y, Mishima Y, et.al
  • Journal Title: Clinical Cancer Research 15(7) Pages: 2523-2523
  • Peer Reviewed
• [Journal Article] Identification of CD20 C-terminal deletion mutations as sociated with loss of CD20 expression in non-Hodgkin's lymphoma (2009)
  • Author(s): Terui Y, Mishima Y, et. al.
  • Journal Title: Clinical Cancer Research 15(7) Pages: 12523-2563
  • Peer Reviewed
• [Journal Article] An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy (2009)
  • Author(s): Mishima Y, Sugimura N, et al
  • Journal Title: Clinical Cancer Research (印刷中)
  • Peer Reviewed
• [Journal Article] CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy (2008)
  • Author(s): Ennishi D, Mishima Y, et.al
  • Journal Title: Annals oncology 19(10)
  • Peer Reviewed
• [Journal Article] がんトランスレーショナルリサーチにおけるバイオイメージングの役割 (2008)
  • Author(s): 三嶋雄二、畠清彦
  • Journal Title: がん分子標的治療 6(2) Pages: 92-92
• [Journal Article] 予後とCirculating Endothelial cells (2008)
  • Author(s): 三嶋雄二、松阪諭、畠清彦
  • Journal Title: Cancer Frontier Pages: 10-10
• [Journal Article] がんトランスレーショナルリサーチにおけるバイオイメージングの役割 (2008)
  • Author(s): 三嶋雄二
  • Journal Title: がん分子標的治療 6(2)
• [Journal Article] CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP t herapy (2008)
  • Author(s): Ennishi D, Mishima Y, et. al.
  • Journal Title: Annals oncology 19(11) Pages: 1921-1926
  • Peer Reviewed
• [Journal Article] Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors (2008)
  • Author(s): Mishima Y, Terui Y, et al
  • Journal Title: Cancer Science 99(11) Pages: 2200-2208
  • NAID: 10024012990
  • Peer Reviewed
• [Journal Article] がんトランスレーショナルリサーチにおけるバイオイメージングの役割 (2008)
  • Author(s): 三嶋雄二, 畠清彦
  • Journal Title: がん分子標的治療 6(2) Pages: 92-100
• [Journal Article] 予後と Circulating Endothelial cells (2008)
  • Author(s): 三嶋雄二, 松阪論, 畠清彦
  • Journal Title: Cancer Frontier 10 Pages: 131-136
• [Journal Article] in vivo 光イメージング (2007)
  • Author(s): 三嶋雄二、畠清彦
  • Journal Title: 病理と臨床 25(6) Pages: 526-526
• [Journal Article] 抗体医薬の補体依存性,抗体依存性殺細胞効果 (2007)
  • Author(s): 三嶋雄二
  • Journal Title: Pharma Medica 25(3) Pages: 9-9
• [Journal Article] in vivo cell biology (2007)
  • Author(s): 三嶋 雄二、畠 清彦
  • Journal Title: 病理と臨床 25(6) Pages: 526-532
• [Journal Article] 抗体医薬の補体依存性,抗体依存性殺細胞効果 (2007)
  • Author(s): 三嶋 雄二
  • Journal Title: Pharma Medica 25(3) Pages: 9-13
• [Presentation] Establishment of an assay system for ADCC activity and search for factors that affect ADCC activity (2008)
  • Author(s): 三嶋雄二, ら
  • Organizer: 日本癌学会
  • Place of Presentation: 名古屋
  • Year and Date: 2008-10-29
• [Presentation] Prediction of clinical response of rituximab containing chemotherapy using newly established live-cell-imaging procedure for estimating CDC susceptibility (2008)
  • Author(s): Mishima Y, et. al
  • Organizer: EORTC-NCI-AACR Molecular Target and Cancer therapeutics
  • Place of Presentation: Geneva, Switzerland
  • Year and Date: 2008-10-21
• [Presentation] 治療前CDC感受性評価法の確立と rituximan 治療効果予測における有用性 (2008)
  • Author(s): 三嶋雄二, ら
  • Organizer: 日本血液学会
  • Place of Presentation: 京都
  • Year and Date: 2008-10-10
• [Presentation] ADCCアッセイシステムの確立とADCC抵抗性因子の探索 (2008)
  • Author(s): 三嶋雄二, ら
  • Organizer: がん分子標的治療研究会
  • Place of Presentation: 東京
  • Year and Date: 2008-06-27
• [Presentation] ADCCアッセイシステムの確立とADCC抵抗性因子の探索 (2008)
  • Author(s): 三嶋雄二
  • Organizer: がん分子標的治療研究会総会
  • Place of Presentation: 東京
• [Presentation] 治療前CDC感受性評価法の確立とrituximab 治療効果予測における有用性 (2008)
  • Author(s): 三嶋雄二
  • Organizer: 第70回日本血液学会
  • Place of Presentation: 京都
• [Presentation] Prediction of clinical response of rituximab containing chemotherapy using newly established live-cell-imaging procedure for estimating CDC susceptibility (2008)
  • Author(s): Yuji Mishima
  • Organizer: Molecular Targetand Cancer Therapeutics
  • Place of Presentation: Geneva, Switzerland
• [Presentation] Establishment of an assay system for ADCC activity and search for factors that affect ADCC activity (2008)
  • Author(s): 三嶋雄二
  • Organizer: 第67回日本癌学会総会
  • Place of Presentation: 名古屋
• [Presentation] Establishment of reproducible ADCC assay system (2007)
  • Author(s): Mishima Y, Terui, Y, et. al.
  • Organizer: Molecular Targetand Cancer Therapeutics
  • Place of Presentation: SanFrancisco
  • Year and Date: 2007-10-24
• [Presentation] Estabhshment of reproducible ADCC assay system (2007)
  • Author(s): 三嶋 雄二、照井 康仁, 他
  • Organizer: 第66回日本癌学会
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2007-10-04
• [Presentation] Development of rapid evaluation system of the Rituximab-mediated complement-dependent cytotoxicity (2007)
  • Author(s): Mishima Y, Terui, Y, et. al.
  • Organizer: MabThera Expert Invetigator Forum
  • Place of Presentation: SanFrancisco
  • Year and Date: 2007-04-21
• [Presentation] Establishment of reproducible ADCC assay system (2007)
  • Author(s): Yuji Mishima
  • Organizer: abthera Expert investigator Forum
  • Place of Presentation: Lisbon, Portugal
• [Presentation] Establishment of reproducible ADCC assay system (2007)
  • Author(s): 三嶋雄二
  • Organizer: 第66回日本癌学会総会
• [Presentation] Establishment of reproducible ADCC assay system (2007)
  • Author(s): Yuji Mishima
  • Organizer: Molecular Targetand Cancer Therapeutics
  • Place of Presentation: San Francisco, USA
• [Presentation] ライブセルイメージングを用いた抗体医薬の予後予測システムの開発 (2007)
  • Author(s): 三嶋雄二
  • Organizer: ダイアローグイメージングセミナー
  • Place of Presentation: 東京
• [Book] がん分子標的治療研究実践マニュアル (CDC, ADCC のアッセイ) (2009)
  • Author(s): 三嶋雄二 畠清彦
  • Publisher: 金芳堂
• [Book] がんの分子標的治療(光イメージング) (2008)
  • Author(s): 三嶋雄二
  • Publisher: 南山堂
• [Book] がんの分子標的治療 (2008)
  • Author(s): 三嶋雄二 (鶴尾孝編)
  • Total Pages: 44
  • Publisher: 南山堂
• [Patent(Industrial Property Rights)] 抗体医薬感受性検査方法 (2007)
  • Inventor(s): 杉村 夏彦, 三嶋 雄二, 畠 清彦
  • Industrial Property Rights Holder: 財団法人癌研究会オリンパス株式会社
  • Filing Date: 2007-09-26
  • Overseas
• [Patent(Industrial Property Rights)] Fc受容体遺伝子導入NK細胞株、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法 (2007)
  • Inventor(s): 杉村 夏彦, 三嶋 雄二, 畠 清彦
  • Industrial Property Rights Holder: 財団法人癌研究会オリンパス株式会社
  • Industrial Property Number: 2007-254099
  • Filing Date: 2007-09-28
• [Patent(Industrial Property Rights)] 抗体医薬感受性検査方法
  • Industrial Property Number: 2006-333331
• [Patent(Industrial Property Rights)] Fc受容体遺伝子導入NK 細胞株、その製造方法、及び抗体依存性細胞傷害のアッセイ方法
  • Industrial Property Number: 2006-333331